Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has announced it will release its third quarter 2024 financial results on November 4, 2024 after US market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has announced it will release its third quarter 2024 financial results on November 4, 2024 after US market close. The company will host an investor conference call and webcast on November 5, 2024 at 8:00 AM ET / 2:00 PM CET to discuss the quarterly results and provide a business update.
Details
News Market Reaction – CLLS
The recorded move for CLLS in the trading session of this news was -2.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market.
The publication will be followed by an investor conference call and webcast on Tuesday, November 5, 2024 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s third quarter results and an update on business activities. Details for the call are as follows:
Dial in information:
Domestic: +1-800-225-9448
International: +1-203-518-9708
Conference ID: CLLSQ3
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1688144&tp_key=affca25222
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit our website: www.cellectis.com
Follow Cellectis on social networks @cellectis on LinkedIn and X (formerly Twitter)
TALEN® is a registered trademark owned by Cellectis.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.